- Home
- LSF vs SNTI Comparison
LSF vs SNTI Comparison
Compare LSF & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | SNTI |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.3M | 29.8M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LSF | SNTI |
|---|---|---|
| Price | $4.74 | $0.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $6.00 | ★ $8.50 |
| AVG Volume (30 Days) | 65.0K | ★ 171.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.28 | ★ 77.31 |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $49,889,286.00 | N/A |
| Revenue This Year | $90.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.18 | ★ N/A |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $1.96 | $0.77 |
| 52 Week High | $7.80 | $2.88 |
Technical Indicators
Market Signals| Indicator | LSF | SNTI |
|---|---|---|
| Relative Strength Index (RSI) | 78.13 | 50.08 |
| Support Level | $2.41 | $0.87 |
| Resistance Level | $5.89 | $1.03 |
| Average True Range (ATR) | 0.29 | 0.06 |
| MACD | 0.13 | -0.00 |
| Stochastic Oscillator | 87.17 | 47.30 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the development and marketing of food and beverage products focused on health and wellness. The company's product portfolio includes coffee creamers, coffee, tea, hot chocolate, hydration and beverage enhancement products, and snacks, made using natural and functional ingredients.
About SNTI Senti Biosciences Inc.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).